Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Application of Myristic Acid and Glycerin Composition in Evaluating the Curative Effect of Chronic Myelogenous Leukemia TKI

A technology of chronic granulocytes and myristic acid, applied in the fields of metabolomics and clinical testing, to achieve the effect of low cost

Active Publication Date: 2020-11-24
THE FIRST AFFILIATED HOSPITAL OF SOOCHOW UNIV
View PDF4 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, there is currently no effective method for early prediction of the efficacy of TKIs in CML patients

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of Myristic Acid and Glycerin Composition in Evaluating the Curative Effect of Chronic Myelogenous Leukemia TKI
  • Application of Myristic Acid and Glycerin Composition in Evaluating the Curative Effect of Chronic Myelogenous Leukemia TKI
  • Application of Myristic Acid and Glycerin Composition in Evaluating the Curative Effect of Chronic Myelogenous Leukemia TKI

Examples

Experimental program
Comparison scheme
Effect test

Embodiment Construction

[0019] The present invention will be further described below in conjunction with specific examples, but the examples are only exemplary and do not constitute any limitation to the scope of the present invention. Those skilled in the art should understand that the details and forms of the technical solutions of the present invention can be modified or replaced without departing from the spirit and scope of the present invention, but these modifications and replacements all fall within the protection scope of the present invention.

[0020] 1. Materials and methods

[0021] 1.1 Research object

[0022] The material discovery group selected 26 patients who were first diagnosed with CML in the chronic phase (CML-CP phase) at the First Affiliated Hospital of Soochow University, and a total of 52 patients with CML-CP phase who received TKI treatment for more than 12 months (according to the treatment The curative effect was divided into treatment success group (26 cases) and treatm...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention provides application of a myristic acid-glycerol composition in evaluating the curative effect of a TKI (Tyrosine Kinase Inhibitor) on chronic myelocytic leukemia (CML), and belongs to the technical fields of metabonomics and clinical examination. In the experiment, a GC-MS (Gas Chromatography-Mass Spectrometer) combined technique is used for researching the plasma small molecular metabolite of CML patients. a newly diagnosed CML group of 26 cases of samples, a TKI treatment success group of 26 cases of samples, a TKI treatment failure group of 26 cases of samples and a health control group of 26 cases of samples are randomly selected to be taken as substance discovery models; verification of 194 cases of samples is performed according to substances screened from small samples. The myristic acid-glycerol combination level of the plasma of the CML patients can be taken as a potential marker for predicting the curative effect of the TKI through sample collection, pretreatment, sample separation and detection, and data processing, and a novel plasma metabolic marker is provided for clinical judgment on the curative effect of the TKI.

Description

technical field [0001] The invention belongs to the technical field of metabolomics and clinical testing, and specifically relates to the use of gas chromatography-mass spectrometry (GC-MS) metabolomics technology to screen the combined levels of myristic acid and glycerol in the plasma of CML patients, which can be used as a predictor of TKI curative effect. potential markers. Background technique [0002] Chronic myelogenous leukemia (CML) is a group of malignant clonal proliferative diseases of the blood system, and its molecular genetics is characterized by the translocation of the long arms of chromosomes 9 and 22, resulting in the BCR-ABL fusion gene, BCR-ABL The expression of fusion gene is mainly through changing the protein tyrosine phosphorylation level of malignant tumor cells, thereby destroying a series of normal signal transduction pathways, and finally leading to the inhibition of cell apoptosis. Tyrosine kinase inhibitor (TKI) is a targeted anti-tumor drug d...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): G01N30/02
CPCG01N30/02
Inventor 吴德沛吴小津杨冰玉王畅韩悦马骁徐良静张翔
Owner THE FIRST AFFILIATED HOSPITAL OF SOOCHOW UNIV
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com